Association of paraoxonase 1 gene polymorphisms with risk of Parkinson's disease: A meta-analysis

Journal of Human Genetics

Volumn 49, Issue 9, 2004, Pages 474-481

  Zintzaras, Elias ^a   Hadjigeorgiou, Georgios M ^b  

^a UNIVERSITY OF THESSALY   (Greece)

^b UNIVERSITY HOSPITAL OF LARISSA   (Greece)

Author keywords

Meta analysis; Paraoxonase; Parkinson's disease; Polymorphism; PON1

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; ASIAN; CASE CONTROL STUDY; CAUCASIAN; CLINICAL TRIAL; DNA POLYMORPHISM; GENE; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HEREDITY; HUMAN; META ANALYSIS; PARKINSON DISEASE; PON1 GENE; RACE DIFFERENCE; RISK FACTOR; STATISTICAL ANALYSIS;

ALLELES; ARYLDIALKYLPHOSPHATASE; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE DETECTION; HUMANS; PARKINSON DISEASE; POLYMORPHISM, GENETIC; RISK ASSESSMENT;

EID: 4744363276     PISSN: 14345161     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10038-004-0176-x     Document Type: Article

References (26)

1. Adkins S, Can KN, Mody M, La Du BN (1993) Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 52:598-608
2. Akhmedova S, Anisimov S, Yakimovsky A, Schwartz E (1999) Gln → Arg 191 polymorphism of paraoxonase and Parkinson's disease. Hum Hered 49:178-180
3. Akhmedova S, Yakimovsky A, Schwartz EI (2001) Paraoxonase 1 Met-Leu 54 polymorphism is associated with Parkinson's disease. J Neurol Sci 184:179-182
4. Carmine A, Buervenich S, Sydow O, Anvret M, Olson L (2002) Further evidence for association of the paraoxonase 1 (PON1) Met-54 allele with Parkinson's disease. Mov Disord 17:764-766
5. Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10:101-129
6. Gowan J, Sinton CM, Varley AW, Wians FH, Haley RW, Munford RS (2001) Gene therapy to prevent organophosphate intoxication. Toxicol Appl Pharmacol 173:1-6
7. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. Br Med J 327:557-560
8. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski C, Furlog CE (1993) The molecular basis of human serum paraoxonase activity polymorphism. Nat Genet 3:73-76
9. Ioannidis JP (1998) Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. J Am Med Assoc 279:281-286
10. Kelada SN, Costa-Mallen P, Checkoway H, Viernes HA, Farin FM, Smith-Weller T, Franklin GM, Costa LG (2003) Paraoxonase 1 promoter and coding region polymorphisms in Parkinson's disease. J Neurol Neurosurg Psychiatry 74:545-548
11. Kondo I, Yamamoto M (1998) Genetic polymorphism of paraoxonase 1 (PON1) and susceptibility to Parkinson's disease. Brain Res 806:271-273
12. Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC (1992) Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 327:248-254
13. Lau J, Ioannidis JP, Schmid CH (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127:820-826
14. Le Couleur DG, McLean AJ, Taylor MC, Woodham BL, Board PG (1999) Pesticides and Parkinson's disease. Biomed Pharmacother 53:122-130
15. Mackness B, Mackness MI, Arrol S, Turkic W, Durrington PN (1997) Effect of the molecular polymorphisms of human paraoxonase (PONl) on the rate of hydrolysis of paraoxon. Br J Pharmacol 122:265-268
16. Mochizuki H, Scherer SW, Xi T, Nickle DC, Majer M, Huizenga JJ, Tsui LC, Prochazka M (1998) Human PON2 gene at 7q21.3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence. Gene 213:149-157
17. Ntais C, Polycarpou A, Ioannidis JP (2003) Association of the CYPl7 gene polymorphism with the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 12:120-126
18. SAGE (2003) Statistical Analysis for Genetic Epidemiology. Computer program package available from Statistical Solutions Ltd, Cork
19. Tan EK, Khajavi M, Thornby JI, Nagamitsu S, Jankovic J, Ashizawa T (2000) Variability and validity of polymorphism association studies in Parkinson's disease. Neurology 55:533-538
20. Taylor MC, Le Couleur DG, Mellick GD, Board PG (2000) Paraoxonase polymorphisms, pesticide exposure and Parkinson's disease in a Caucasian population. J Neural Transm 107:979-983
21. Wang J, Liu Z (2000) No association between paraoxonase 1 (PONl) gene polymorphism and susceptibility to Parkinson's disease in a Chinese population. Mov Disord 15:1265-1267
22. Warner TT, Schapira AHV (2003) Genetic and environmental factors in the cause of Parkinson's disease. Ann Neurol 53(Suppl 3):S16-S25
23. Weir BS (1996) Genetic data analysis II: methods for discrete population genetic data. Sinauer Associates, Sunderland
24. Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J (2004) Four paraoxonase gene polymorphisms in 11,212 cases of coronary heart disease and 12,786 controls: meta-analysis of 43 studies. Lancet 363:689-695
25. Whitehead A (1997) A prospectively planned cumulative meta-analysis applied to a series of concurrent clinical trials. Stat Med 16:2901-2913
26. Whitehead A (2002) Meta-analysis of controlled clinical trials. Wiley, Chichester